Special Issue "Current and Upcoming Diagnostics and Prognostics in Multiple Myeloma"

A special issue of Hemato (ISSN 2673-6357). This special issue belongs to the section "Plasma Cell Disorders".

Deadline for manuscript submissions: closed (30 September 2021).

Special Issue Editor

Dr. Fredrik Schjesvold
E-Mail Website
Guest Editor
1. Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway
2. KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway
Interests: clinical studies in myeloma; PET-CT; MRD-driven trials

Special Issue Information

Dear colleagues,

The development of diagnostic and prognostic procedures in multiple myeloma is progressing with significant pace, giving deeper and more substantial information for myeloma patients. The genetic constitution of the clonal plasma cells, analyzed from bone marrow, circulating cells and DNA, as well as the increased information from developing radiological and nuclear-medicine methods, will enable more personalized treatment and follow-up in the future. Our methods of follow-up are also advancing, with more sensitive techniques of measuring minimal residual disease (MRD) laying the ground for studies intensifying and de-intensifying treatment according to the response status of the patient.

In this Special Issue, we trail the current and future statuses of these topics, showing where we are and where we are going.

Dr. Fredrik Schjesvold
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MRD (minimal residual disease)
  • PET (positron emission tomography)
  • Mass-spec
  • Mutations
  • FISH (fluorescent in situ hybridization)
  • DW-MRI (diffusion-weighted magnetic resonance imaging)

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop